Choi Hayoung, Lee Hyun, Jeon Kyeongman, Suh Gee Young, Shin Sumin, Kim Hong Kwan, Kim Kyunga, Jeong Daecheon, Kim Hojoong
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea.
Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
J Thorac Dis. 2019 Mar;11(3):892-900. doi: 10.21037/jtd.2019.01.75.
Surgical resection is the cornerstone treatment for pulmonary mucormycosis, a lethal fungal infection. It is unclear why some patients do not receive surgery, and the natural courses of these patients have not been well evaluated.
A retrospective review was performed using the medical records of 20 patients with pathologically-confirmed pulmonary mucormycosis. We evaluated the reasons for not receiving surgery and compared treatment outcomes between patients who did and did not undergo surgery.
Overall survival rate was 50%. Nine of 11 (82%) patients who underwent surgery survived; however, only 1 of 9 (11%) patients who did not undergo surgery survived. Reasons for not receiving surgery were death shortly after diagnosis (n=1), altered mental state (n=1), refractory underlying disease (n=3), and refusal by patient due to concern of operative risk (n=4). Patients who did not undergo surgery were more likely to be older (P=0.018), have a longer duration of steroid use (P=0.021), higher lactate dehydrogenase level (P=0.039), higher sequential organ failure assessment (SOFA) score (P=0.035), and higher rate of cytomegalovirus (CMV) infection (P=0.020) than those did receive surgery. Surgery was the only favorable survival factor in multivariable analyses (adjusted odds ratio for survival =15.45; P=0.029).
The main reasons for not undergoing surgery in patients with pulmonary mucormycosis were the gravity of underlying diseases and concerns for operative risk. Although overall survival rate was poor, it was significantly higher in patients who received pulmonary resection surgery. The decision to undergo lung resection is time-sensitive and essential in improving survival rate in patients suffering from pulmonary mucormycosis, despite perioperative risks.
手术切除是治疗肺毛霉菌病(一种致命的真菌感染)的基石性治疗方法。目前尚不清楚为何有些患者未接受手术治疗,且这些患者的自然病程也未得到充分评估。
对20例经病理确诊的肺毛霉菌病患者的病历进行回顾性分析。我们评估了未接受手术的原因,并比较了接受手术和未接受手术患者的治疗结果。
总体生存率为50%。11例接受手术的患者中有9例(82%)存活;然而,9例未接受手术的患者中仅有1例(11%)存活。未接受手术的原因包括诊断后不久死亡(n = 1)、精神状态改变(n = 1)、难治性基础疾病(n = 3)以及患者因担心手术风险而拒绝手术(n = 4)。未接受手术的患者比接受手术的患者年龄更大(P = 0.018)、使用类固醇的时间更长(P = 0.021)、乳酸脱氢酶水平更高(P = 0.039)、序贯器官衰竭评估(SOFA)评分更高(P = 0.035)以及巨细胞病毒(CMV)感染率更高(P = 0.020)。在多变量分析中,手术是唯一有利的生存因素(生存调整比值比 = 15.45;P = 0.029)。
肺毛霉菌病患者未接受手术的主要原因是基础疾病严重和担心手术风险。尽管总体生存率较低,但接受肺切除手术的患者生存率显著更高。尽管存在围手术期风险,但对于肺毛霉菌病患者而言,决定是否进行肺切除手术对提高生存率至关重要且具有时间敏感性。